Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Aug 20, 2019 in Leukemia | 0 comments

In a nutshell

This study aimed to investigate if sorafenib (Nexavar) would be a suitable maintenance agent for patients with acute myeloid leukemia who received a stem cell transplant.  

This study concluded that sorafenib is a safe and effective maintenance agent in these patients.  

Some background

Patients with acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 (FLT3) mutations have a very poor prognosis. These patients are normally treated with allogeneic hematopoietic stem cell transplant (allo-HSCT) and salvage treatments. Allo-HSCT is a procedure in which a patient receives blood-forming stem cells from a genetically similar, but not identical, donor. This is often a sister or brother but could be an unrelated donor. Salvage treatment is a form of therapy given after cancer does not respond to standard therapy.  

Sorafenib is a type of targeted therapy called a kinase inhibitor. It is approved for use in FLT3 AML. Maintenance therapy is a chemotherapy given in lower doses to assist in prolonging remission. It was unknown if sorafenib could be used as a maintenance therapy after allo-HSCT in AML patients. 

Methods & findings

This study involved 27 patients with FLT3-mutated AML who received allo-HSCT as a treatment. Patients were followed up for an average of 40 months. 

A previous report indicated that sorafenib was safe and effective as a maintenance agent after allo-HSCT in patients with FLT3-mutated AML. Significant overall survival (OS) and progression-free survival (PFS) has been seen in patients who received sorafenib before and/or after allo-HSCT.  

In this updated study, the persistence of previously reported long-term disease control was demonstrated. The 2-years PFS was on average 73% and the 2-years OS was 80%. 

The bottom line

This study concluded that sorafenib is a safe and effective maintenance agent for patients with FLT3-mutated AML who received allo-HSCT.  

The fine print

This study had a very small number of patients. Further studies on larger populations are needed.

Published By :

Clinical lymphoma, myeloma & leukemia

Date :

Aug 01, 2019

Original Title :

Efficacy and Feasibility of Sorafenib as a Maintenance Agent After Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Mutated Acute Myeloid Leukemia: An Update.

click here to get personalized updates